Aprea Therapeutics (APRE) Profit After Tax (2018 - 2026)

Aprea Therapeutics (APRE) has reported Profit After Tax for 9 consecutive years, with -$3.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 16.62% year-over-year to -$3.3 million; the TTM figure through Mar 2026 stood at -$11.9 million (up 15.17% YoY), while the FY2025 annual figure was -$12.6 million, up 2.89% from the prior year.
• Profit After Tax declined to -$3.3 million in Q1 2026 per APRE's latest filing, from -$2.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$2.5 million in Q4 2025 and bottomed at -$98.3 million in Q2 2022.
• Historically, Profit After Tax has averaged -$9.2 million across 5 years, with a median of -$3.3 million in 2026.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 858.52% — and 2023, when it surged 96.68%.
• Aprea Therapeutics' Profit After Tax stood at -$2.8 million in 2022, then fell by 21.02% to -$3.4 million in 2023, then gained by 14.66% to -$2.9 million in 2024, then rose by 15.9% to -$2.5 million in 2025, then sank by 33.64% to -$3.3 million in 2026.
• Business Quant data shows APRE's Profit After Tax at -$3.3 million in Q1 2026, -$2.5 million in Q4 2025, and -$3.0 million in Q3 2025.